NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.
While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.
Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.
Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.